Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant main » significant gap (Expand Search), significant amount (Expand Search), significant cause (Expand Search)
main decrease » gain decreased (Expand Search), mean decrease (Expand Search), point decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant main » significant gap (Expand Search), significant amount (Expand Search), significant cause (Expand Search)
main decrease » gain decreased (Expand Search), mean decrease (Expand Search), point decrease (Expand Search)
-
881
Forest plot for TNF-
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
882
Bias risk assessment of included studies.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
883
Forest plot for hs-CRP.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
884
Forest plot for IL-6.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
885
The incidence rate of adverse reactions.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
886
The PRISMA study flowchart.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
887
Forest plot for FEV1/FVC.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
888
Forest plot for clinical efficacy.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
889
Forest plot for FEV1.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
890
The excluded and included studies were listed.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
891
Forest plot for PaCO<sub>2</sub>.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
892
Forest plot for PaO<sub>2</sub>.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
-
893
-
894
-
895
Land use intensity classes standard.
Published 2025“…The habitat quality shows a spatial distribution pattern of “high in the surrounding areas and low in the central areas”, and autocorrelation analysis shows that county-level units have significant spatial agglomeration effects. (iii) The overall type shows an enhancement of dual factor or non-linear, in which land use intensity and population density are the main driving factors for the spatio-temporal evolution of habitat quality. …”
-
896
Land use transfer matrix 1990-2020 (km<sup>2</sup>).
Published 2025“…The habitat quality shows a spatial distribution pattern of “high in the surrounding areas and low in the central areas”, and autocorrelation analysis shows that county-level units have significant spatial agglomeration effects. (iii) The overall type shows an enhancement of dual factor or non-linear, in which land use intensity and population density are the main driving factors for the spatio-temporal evolution of habitat quality. …”
-
897
Study area habitat quality LISA clustering map.
Published 2025“…The habitat quality shows a spatial distribution pattern of “high in the surrounding areas and low in the central areas”, and autocorrelation analysis shows that county-level units have significant spatial agglomeration effects. (iii) The overall type shows an enhancement of dual factor or non-linear, in which land use intensity and population density are the main driving factors for the spatio-temporal evolution of habitat quality. …”
-
898
Spato-temporal changes in land use types.
Published 2025“…The habitat quality shows a spatial distribution pattern of “high in the surrounding areas and low in the central areas”, and autocorrelation analysis shows that county-level units have significant spatial agglomeration effects. (iii) The overall type shows an enhancement of dual factor or non-linear, in which land use intensity and population density are the main driving factors for the spatio-temporal evolution of habitat quality. …”
-
899
Pattern indices of landscape levels.
Published 2025“…The habitat quality shows a spatial distribution pattern of “high in the surrounding areas and low in the central areas”, and autocorrelation analysis shows that county-level units have significant spatial agglomeration effects. (iii) The overall type shows an enhancement of dual factor or non-linear, in which land use intensity and population density are the main driving factors for the spatio-temporal evolution of habitat quality. …”
-
900
Type level landscape index changes in 1990-2020.
Published 2025“…The habitat quality shows a spatial distribution pattern of “high in the surrounding areas and low in the central areas”, and autocorrelation analysis shows that county-level units have significant spatial agglomeration effects. (iii) The overall type shows an enhancement of dual factor or non-linear, in which land use intensity and population density are the main driving factors for the spatio-temporal evolution of habitat quality. …”